Spruce Biosciences’ stock plummets in wake of PhIIb flop, biotech to cut staff
Spruce Biosciences’ tildacerfont failed a Phase IIb test in adults with congenital adrenal hyperplasia (CAH) due to compliance issues, crushing its stock $SPRB by as much as 75% premarket.
In the 96-patient CAHmelia-203 trial, the oral CRF1 receptor antagonist did not meet the primary endpoint of change in androstenedione (A4) levels at 12 weeks. The company said there was low compliance with the drug and standard of care glucocorticoid (GC) steroids, with only about half of patients noting they were at least 80% compliant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
